


Advanced Therapeutics within Everyone's Reach

# CELLTRION IR Presentation

November & December 2024



## Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any liability resulting from investors' reliance on the information contained herein.



# CONTENTS

- I. Business Overview
- II. Biosimilar
- III. Novel Drug
- IV. Sales Network & Production
- V. Financials
- VI. Appendix



01

# Business Overview


---

- Group Growth Story
- Key Highlights

# Celltrion Group Growth Story

✓ Revenue Trend [Unit: KRW billion]

“  
CAGR  
30% Up  
Since 2002  
”



\*The launch date for each product is based on the date it was first released in the global market.

# Key Highlights

## Emerging as a Top-tier Global Pharma with Best-in-Class Biosimilar & Novel Drug Capabilities



### Biosimilar

- Commercialize a total of 22 products by 2030
- Target a broad range of therapeutic areas with differentiated formulation, administration routes and dosage



### Novel Drug

- Successful US market entry of Zymfentra via proactive marketing initiatives
- Bolster novel drug pipelines through M&A and other initiatives



### Sales Network

- Established direct sales system in the EU and the US in 2019 and 2023, respectively
- Broaden market presence across emerging countries while establishing an extensive global direct distribution network



### In-house Production

- 250,000L of own drug substance capacity in Songdo, South Korea
- Able to manufacture approximately 18 million syringes annually from Celltrion Pharm



02

# Biosimilar

---


- Biosimilar Landscape
- Biosimilar Portfolio & Pipeline
- Global Commercial Update

# Biosimilar Landscape

Despite overheated competition from new entrants,  
Only a Few Key Players with Strong Portfolio & Commercialization Capabilities Lead the Market



1. Number of companies that conducted global clinical trials(pre-clinical to phase 3) on the same molecules of Celltrion's portfolio or pipeline  
2. Based on FY2023 sales




1. Competitors with annual biosimilar sales of over \$500 million  
2. Aside from the main competitors, companies developing two or more products with the same molecules as those in our pipeline  
3. Number of products: the sum of FDA and EMA-approved monoclonal antibody biosimilars and disclosed pipeline products

# Biosimilar Portfolio & Pipeline


## Increasing Market Presence via Biosimilar Expansion & Product Differentiation



### Biosimilar Timeline



### Target Pipeline Market Size





1. Intravenous injection  
2. Subcutaneous injection  
3. Intravitreal injection

\* Combined sales of 22 original products in the pipelines  
\*\* Source: IQVIA

# Global Commercial Update: Remsima / Inflectra (Infliximab IV)

Maintaining a Strong and Stable Presence in the Global Market,  
Holding 60% M/S in Europe and double the share of competing biosimilars in the U.S.




\*Based on Infliximab IV Market (Excluding SC) \*Market shares are based on prescription volume \*Source: IQVIA


\*Based on INFLIXIMAB IV Market (Excluding SC) \*Market shares are based on prescription volume  
\*US market share data is based on IQVIA starting from 4Q23 due to the cessation of data provision by Symphony Health  
\*Source: Symphony Health, IQVIA

# Global Commercial Update: Remsima SC

**Remsima IV+SC Combined Achieved 76% M/S in EU5,**  
**with Remsima SC Capturing 24% M/S in EU5 and market share gains in ex-EU5 European countries**



\* Data based on prescription volume      \* Source: IQVIA      \* EU5: UK, Spain, France, Germany, Italy



\* Data based on prescription volume      \* Source: IQVIA  
\* Patient numbers are calculated by dividing the total infliximab prescription volume by the average annual dosage frequency (IV 34 times, SC 24 times)  
\* The estimated 2024 patient numbers are based on the patient count from 1H24

#### Remsima M/S in EU5\*\*

\*\*Total M/S of Remsima IV & SC

**UK**  
88.0%

**FRANCE**  
77.3%


**SPAIN**  
74.7%

**GERMANY**  
71.0%


**ITALY**  
50.6%

# Global Commercial Update: Truxima & Herzuma

Truxima and Herzuma continues global market share gains driven by **Merger Effects** with Truxima **Gaining ~30% M/S in Europe & US**, Herzuma achieving growth in Europe and **~70% M/S in Japan**



1. The U.S. market share data is based on IQVIA from 4Q23 onwards due to the discontinuation of data provision by Symphony Health  
\* Market Share based on prescription volume      \* Source: IQVIA, Symphony Health




\* Market Share based on prescription volume      \* Source: IQVIA, Market DATA

# Global Commercial Update: Yuflyma

Accelerated growth in the European market through country-specific bidding strategies,  
**Achieving more than 1.7x 2023 Annual Sales by 3Q24**


## Europe M/S trend of Yuflyma and Competing Products



\* M/S based on prescription volume

\* Source: IQVIA

## Yuflyma Global Sales Trend




\* ~ 4Q23: pre-merger Celltrion Healthcare's sales

1Q24~ : Post-merger Celltrion's sales

# Global Commercial Update: Vegzelma

Secured 2<sup>nd</sup> place in market share through long-term bid wins across major European markets,  
**Achieving more than 2.9x 2023 Annual Sales by 3Q24**

## Europe M/S trend of Vegzelma and Competing Products



M/S in key European countries



**FINLAND**  
92.5%



**UK**  
33.2%




**GERMANY**  
24.7%

\* M/S based on prescription volume

\* Source: IQVIA

## Vegzelma Global Sales Trend



\* ~ 4Q23: pre-merger Celltrion Healthcare's sales

1Q24~ : post-merger Celltrion's sales



03

## Novel Drug


---

- Journey to Antibody Powerhouse
- Innovative Drug Pipeline
- Key Takeaways from World ADC
- Zymfentra

# Celltrion's Journey to Antibody Powerhouse

With 20 years of Experience in Antibody R&D, Production & Commercialization  
“ Transforming from a Biosimilar Leader to an Innovator ”

Developed the world's first  
mAb biosimilar & Successfully  
marketed 6 biosimilars



cGMP manufacturing facilities  
with a total capacity of 250,000L



Developed and gained approval for  
novel antibody drug 'Regkirona'  
in just 1 year



Obtained approval by  
MFDS<sup>1</sup> & EU EMA<sup>2</sup>

Acquired proprietary technology  
through open innovation



Closed a licensing  
deal for ADC  
Platform technology



Co-developing  
bispecific antibodies

IND submission within 2 years of  
embarking on novel drug  
development

2024.11

Unveiled CT-P70 and CT-P71  
pre-clinical results  
at the 2024 World ADC

2025

IND submission planned for  
3 ADC pipelines


2025

IND submission planned for  
a multispecific pipeline

1. Ministry of Food and Drug Safety(MFDS) of Korea  
2. European Medicines Agency


# Innovative Drug Pipeline

✓ : ADC & Multispecific Antibodies




# Key Takeaways from World ADC

Making its debut at the world’s largest ADC conference ‘World ADC 2024’ to present CT-P70 & CT-P71 preclinical results, **with plans for a Phase1 IND submission next year**



1. c-MET(Mesenchymal-Epithelial Transition factor) : A protein that plays an important role in the physiological processes of cells, with overexpression or mutations observed in cancer cells promoting progression

2. Topo1i(Topoisomerase 1 Inhibitors): A drug that inhibits the enzyme called Topo 1, preventing the enzyme from rejoining DNA during the unwinding process, thereby causing DNA damage



3. TGI: Tumor Growth Inhibition

4. Nectin-4: A cell adhesion protein that is overexpressed in various solid tumors, including metastatic urothelial carcinoma

# Zymfentra : Unlocking Growth Opportunities (1/4)



## Product Competitiveness

### First and Only Sub-Q Infliximab

- High efficacy achieved through elevated and consistent serum level
- Improves patients' quality of life with convenient self-injection method

## Patent Protection

### Patent Protection until 2037 – 2040

- Formulation patent valid until 2037
- Administration patent valid until 2038~2040

## Rapid Market Penetration

### Listed on TOP 3 PBMs' Formularies

- Infliximab's 20+ years of proven safety and efficacy expedited negotiation process for Zymfentra's listing with major PBMs



## High Profitability

### High WAC<sup>1</sup> and Strong NSP<sup>2</sup> Positioning

- Higher WAC of sub-Q formulation compared to IV formulation
- Higher NSP with relatively lower rebates than biosimilars


1. WAC: Wholesale Acquisition Cost

2. NSP: Net Sales Price



# Zymfentra: Key Achievements (2/4)

**Poised for Delivering Significant Prescription Growth  
& Emerging as Blockbuster Drug**  
driven by formulary listings with 3 major PBMs and full-fledged marketing campaigns




# Zymfentra: Sales Trend (3/4)

- Steady growth maintained since April, with prescription volume expected to expand for Q4 following active advertising campaigns started in Sep.
- Reimbursement process with key PBM-affiliated insurers being finalized; accelerated growth anticipated once completed(1Q25)


## ▶ NSP (Prescription Volume) Trend

(Syringe)



## ▶ Shipment Volume Trend

(Syringe)



\* Pack Unit (the IQVIA base unit) converted into the number of individual pens

\* Source: IQVIA SMART NSP (National Sales Perspectives), Company Data

# Zymfentra: ACG Conference Highlights (4/4)

ACG Guideline

HCPs attending the conference



**Globally renowned  
gastroenterology guidelines**

**8,000**



Anticipated Benefits

Demonstrated Zymfentra's efficacy and safety  
in a presentation by esteemed gastroenterologist Bruce E. Sands




- ✓ Zymfentra monotherapy's efficacy and safety were compared to those of combination therapy (immunosuppressants + infliximab) over 102 weeks
- ✓ The efficacy and safety were comparable between monotherapy and combination therapy, providing evidence that monotherapy could potentially replace combination therapy.


## Week 102 Efficacy Results<sup>1</sup> (by concentration tertile<sup>2</sup> group)

● Combination therapy ● Monotherapy


Clinical remission\*



Endoscopic remission



Endoscopic response



## Patient Switch & Prescription Expansion

### Provided scientific evidence

to reassure and attract physicians unfamiliar  
with sub-q formulation of INFLIXIMAB

### Boosting market interest and strengthening trust

through ongoing clinical result disclosures  
following the U.S. DDW and European  
UEGW

1. <Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (CT-P13 SC) Monotherapy versus Combination Therapy with Immunosuppressants – Post hoc Analysis of LIBERTY-CD AND LIBERTY-UC Studies>, Bruce E. Sands et al., 2024

2. T(Tertile): patients grouped into three according to blood serum level after administration(T1 ≤8.19 µg/mL; T2 8.19 to ≤16.9 µg/mL; T3 >16.9 µg/mL, UC: T1 ≤9.68 µg/mL; T2 9.68 to ≤16.3 µg/mL; T3 >16.3 µg/mL)


# 04

## **Sales Network & Production**

- Global Sales Network Roadmap
- Production Facility & Capacity
- Fully Integrated Biopharma Value Chain

# Global Sales Network Roadmap

Expanding direct sales network to enable flexible pricing and bundling strategy



# Production Facility & Capacity

**250,000L of Own Drug Substance Capacity  
Sufficient to Meet Demand for Successor Pipelines**



**100,000L**

**12,500L X 8 lines**

- First to be approved by US FDA as animal cell culture facility in Asia



**90,000L**

**15,000L X 6 lines**

- Capable of manufacturing drug substance and fill and finish of drug product



**60,000L**

**7,500L X 8 lines**

- Small-scale production for multiple products along with diversification of product portfolio
- Commercial operation to begin in 4Q24

# Fully Integrated Biopharma Value Chain







05

# Financials

---

- Biologics Sales Trend by Region and Product
- 3Q24 Financial Highlights (Consolidated)
- 2024 Earnings: Key Considerations
- Quarterly Sales Mix
- Biologics Global Market Sales

# Biologics Sales Trend by Region and Product



\* '14-'23: Pre-merger Celltrion Healthcare's Sales  
\*\* 3Q24: Sales after the merger

# 3Q24 Financial Highlights (Consolidated)

Robust sales fueled by growth in global biologics prescriptions  
**The OP margin reached 23.6%, attributed to improved COGS & reduced PPA amortization**

[Unit: KRW billion]

|                  | 3Q24  | 2Q24  | QoQ     | 3Q23  | YoY     |
|------------------|-------|-------|---------|-------|---------|
| Sales            | 881.9 | 874.7 | +0.8%   | 672.3 | +31.2%  |
| Biologics        | 810.0 | 774.0 | +4.7%   | 462.2 | +75.2%  |
| Non-Biologics    | 71.9  | 100.7 | -28.6%  | 210.1 | -65.8%  |
| Operating Profit | 207.7 | 72.5  | +186.5% | 267.6 | -22.4%  |
| OP margin        | 23.6% | 8.3%  | +15.3%p | 39.8% | -16.2%p |

## Sales Increased +31.2% YoY


- Cumulative sales for the three quarters reached 2.49 trillion KRW, hovering above the annual sales of 2023(2.17 trillion KRW)
  - Sales of biologics rose significantly by +75.2% YoY, driven by the rapid growth of new products such as Remsima SC, Yuflyma, and Vegzelma
  - Non-biologics sales decreased by -65.8% YoY due to deferred CMO sales and reduced revenue for DP services following the merger

## OP Declined -22.4% YoY

- Profitability is recovering rapidly due to improvements in the COGS ratio(from 58.0% in 2Q24 to 47.5% in 3Q24) and a notable decrease in merger-related amortization, resulting in an operating profit margin of 23.6%
  - The GP Margin improved by 10.5%p QoQ, reaching 52.5%. Margin improvement is expected to continue due to ① an improved inventory mix resulting from the rapid digestion of inventory previously held by Celltrion Healthcare and the production of lower-cost drug substances, and ② an increase in sales of high-profit new products
  - The amortization of sales rights following the merger(113.7bn KRW) was completed in 1H24, with the remaining PPA amortization decreasing to around 7 billion KRW each quarter


# 2024 Earnings: Key Considerations

Sales trends over the past three years




- Cumulative sales for 3Q24 have hovered above the total annual sales for 2023
- **Annual sales** for 2024 **are anticipated to surpass the guidance of 3.5 trillion KRW**

Trend forecast of inventory assets and COGS ratio with gross average method applied




- **Accelerated improvement in COGS ratio** driven by rapid digestion of high-cost inventory and new production effects

Trend of quarterly OP margins for 2024



- **The OP Margin improved +15.3%p** compared to the previous quarter, **returning to the mid-20% range**

# Quarterly Sales Mix



## 1 Biologics

- New biosimilar sales increased +112.5% YoY and +46.7% QoQ, emerging as a new growth driver

## 2 Non-Biologics

- Non-Biologics sales decreased -65.8% YoY due to deferred CMO revenue and DP service revenue decline following the merger

\*For comparability, 3Q23 biopharmaceutical sales is based on the pre-merger Celltrion Healthcare's sales, while non-biopharmaceutical sales is based on Celltrion's.


3Q23 chemical drug sales is based on Celltrion Pharm's sales, excluding Celltrion Pharm's biopharmaceutical sales.

\*\*The sales of chemical drugs from Celltrion Pharm(subsidiary) is included

# Biologics Global Market Sales


## Sales Proportion by Product

[Unit: KRW billion]



## Sales Proportion by Region

[Unit: KRW billion]



- Growth momentum largely driven by new biosimilars: sales mix of new biosimilars expanded from 25.8% in 3Q23 to 42.3% in 3Q24
  - Quarterly sales of new biosimilars increased +112.5% YoY
- Remsima SC, Yuflyma, and Vegzelma all hit record-high quarterly sales
  - Robust quarterly sales of Remsima IV grew to the 300 billion KRW range, while Remsima SC(+68.7% YoY, +53.7% QoQ) reached a stable sales of the high 100 billion KRW range
  - Yuflyma and Vegzelma sales have been growing rapidly, driven by bid wins in major European countries, and SteQeyma began generating revenues as its sales kicked in

- Europe: Accelerating sales growth with expansion of new products while core products maintain stable revenue base(+56.9% YoY, +24.1% QoQ)
  - Remsima SC recorded the highest quarterly sales with continuous sales growth in entire Europe beyond EU5
  - Sales growth driven by Yuflyma and Vegzelma's successful bid wins in major European countries
- North America: Despite the quarterly sales decrease due to Inflectra's significant sales growth in last quarter, accumulated 3Q24 sales hovered above 2023 annual sales driven by the growth across all products

\* 3Q23: Pre-merger Celltrion Healthcare's sales

\*\* 2Q24, 3Q24 : Sales after the merger

\* 3Q23: Pre-merger Celltrion Healthcare's sales

\*\* 2Q24, 3Q24 : Sales after the merger

06

## Appendix

---

- Biologics Portfolio & Pipeline List
- Earnings Summary
- Quarterly Sales Mix
- Shareholder Return Policy

# Biologics Portfolio & Pipeline List

| Product               | Molecule      | Original               | Indications                                                                                                                                                                                                 | US Status           | EU Status        |
|-----------------------|---------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------|
| Remsima/<br>Inflectra | Infliximab    | Remicade®              | Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn’s Disease(CD), etc.                                                                                                                                 | 2H16<br>Launched    | 1H13<br>Launched |
| Remsima SC            | Infliximab    | Remicade®              | Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn’s Disease(CD), etc.                                                                                                                                 | -                   | 1H20<br>Launched |
| Zymfentra             | Infliximab    | Novel Drug             | Ulcerative Colitis(UC), Crohn’s Disease(CD)                                                                                                                                                                 | 1H24<br>Launched    | -                |
| Yuflyma               | Adalimumab    | Humira®                | Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn’s Disease(CD), etc.                                                                                                                                 | 1H23<br>Launched    | 1H21<br>Launched |
| Truxima               | Rituximab     | Rituxan®/<br>MabThera® | Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), etc.                                                                                                                                        | 2H19<br>Launched    | 1H17<br>Launched |
| Herzuma               | Trastuzumab   | Herceptin®             | HER2-Positive Metastatic Breast Cancer(MBC), Early Breast Cancer(EBC), etc.                                                                                                                                 | 1H20<br>Launched    | 1H18<br>Launched |
| Vegzelma              | Bevacizumab   | Avastin®               | Metastatic Colorectal Cancer(MCC), Non-Small Cell Lung Cancer(NSNLC), etc.                                                                                                                                  | 1H23<br>Launched    | 2H22<br>Launched |
| Omlyclo               | Omalizumab    | Xolair®                | Allergic Asthma, Chronic Spontaneous Urticaria(CSU), etc.                                                                                                                                                   | Under Review        | EMA Approved     |
| SteQeyma              | Ustekinumab   | Stelara®               | Psoriasis(Ps), Psoriatic Arthritis(PsA), Ulcerative Colitis(UC), Crohn’s Disease(CD), etc.                                                                                                                  | Under Review        | 2H24<br>Launched |
| Eydenzelt             | Aflibercept   | Eylea®                 | Wet age-related Macular Degeneration(AMD), Diabetic Macular Edema(DME), etc.                                                                                                                                | Under Review        |                  |
| CT-P41                | Denosumab     | Prolia® & Xgeva®       | Osteoporosis, Multiple Myeloma(MM), Giant Cell Tumor(GCT), etc.                                                                                                                                             | Under Review        |                  |
| CT-P47                | Tocilizumab   | Actemra®               | Rheumatoid Arthritis(RA), Giant Cell Arteritis(GCA), Systemic Juvenile Idiopathic Arthritis(SJIA), etc.                                                                                                     | Under Review        |                  |
| CT-P53                | Ocrelizumab   | Ocrevus®               | Multiple Sclerosis(MS)                                                                                                                                                                                      | In Clinical Phase 3 |                  |
| CT-P55                | Secukinumab   | Cosentyx®              | Plaque Psoriasis(PsO), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis, (nr-axSpA), Enthesitis-Related Arthritis (ERA), Hidradenitis Suppurative (HS) etc. | In Clinical Phase 3 |                  |
| CT-P51                | Pembrolizumab | Keytruda®              | Non-Small Cell Lung Cancer(NSNLC), Melanoma, Urothelial Carcinoma etc.                                                                                                                                      | In Clinical Phase 3 |                  |

# Earnings Summary

Consolidated

[Unit: KRW million]

|                                  | Quarterly |         |         |          |         |         |          | Yearly    |           |           |
|----------------------------------|-----------|---------|---------|----------|---------|---------|----------|-----------|-----------|-----------|
|                                  | 1Q23      | 2Q23    | 3Q23    | 4Q23     | 1Q24    | 2Q24    | 3Q24     | FY2021    | FY2022    | FY2023    |
| Sales                            | 597,564   | 523,978 | 672,292 | 382,598  | 736,980 | 874,741 | 881,933  | 1,893,401 | 2,283,967 | 2,176,432 |
| Cost of Sales                    | 333,387   | 247,808 | 301,942 | 241,425  | 430,311 | 506,913 | 418,519  | 805,807   | 1,251,270 | 1,124,562 |
| Gross Profit                     | 264,177   | 276,170 | 370,349 | 141,172  | 306,669 | 367,829 | 463,414  | 1,087,594 | 1,032,697 | 1,051,869 |
| GP Margin                        | 44.2%     | 52.7%   | 55.1%   | 36.9%    | 41.6%   | 42.1%   | 52.5%    | 57.4%     | 45.2%     | 48.3%     |
| SG&A                             | 81,742    | 93,176  | 102,720 | 122,749  | 291,232 | 295,341 | 255,728  | 343,417   | 385,499   | 400,388   |
| - R&D Expenses                   | 29,926    | 39,032  | 41,744  | 50,411   | 49,486  | 36,147  | 52,927   | 125,769   | 139,714   | 161,112   |
| Operating Profit                 | 182,435   | 182,994 | 267,629 | 18,423   | 15,437  | 72,488  | 207,686  | 744,177   | 647,198   | 651,481   |
| OP Margin                        | 30.5%     | 34.9%   | 39.8%   | 4.8%     | 2.1%    | 8.3%    | 23.5%    | 39.3%     | 28.3%     | 29.9%     |
| Other Non-operating Profit/Loss* | 21,010    | 2,680   | 6,303   | (21,866) | 5,619   | 38,953  | (18,691) | (35,050)  | (32,464)  | 8,126     |
| Financial Income/Loss            | 4,844     | 4,025   | 8,952   | (6,333)  | (1,379) | (7,244) | (10,746) | 29,497    | 11,439    | 11,488    |
| Profit before Income Tax         | 208,289   | 189,699 | 282,884 | (9,776)  | 19,678  | 104,197 | 178,249  | 738,623   | 626,173   | 671,096   |
| Net Profit                       | 167,143   | 150,873 | 221,238 | 453      | 20,768  | 78,452  | 84,094   | 595,779   | 542,566   | 539,707   |
| NP Margin                        | 28.0%     | 28.8%   | 32.9%   | 0.1%     | 2.8%    | 9.0%    | 9.5%     | 31.5%     | 23.8%     | 24.8%     |

\* Other non-operation profit/loss includes the net gain/loss on equity method valuation

# Earnings Summary

Non-consolidated

[Unit: KRW million]

|                                  | Quarterly |         |         |          |         |         |           | Yearly    |           |           |
|----------------------------------|-----------|---------|---------|----------|---------|---------|-----------|-----------|-----------|-----------|
|                                  | 1Q23      | 2Q23    | 3Q23    | 4Q23     | 1Q24    | 2Q24    | 3Q24      | FY2021    | FY2022    | FY2023    |
| Sales                            | 535,580   | 422,964 | 600,020 | 314,866  | 638,245 | 973,197 | 1,039,932 | 1,615,840 | 1,937,469 | 1,873,430 |
| Cost of Sales                    | 296,117   | 196,613 | 265,528 | 196,941  | 457,461 | 492,989 | 457,989   | 685,971   | 1,052,058 | 955,199   |
| Gross Profit                     | 239,463   | 226,351 | 334,492 | 117,925  | 180,784 | 480,208 | 581,943   | 929,869   | 885,411   | 918,231   |
| GP Margin                        | 44.7%     | 53.5%   | 55.7%   | 37.5%    | 28.3%   | 49.3%   | 56.0%     | 57.5%     | 45.7%     | 49.0%     |
| SG&A                             | 53,940    | 63,397  | 70,323  | 92,082   | 151,999 | 167,152 | 120,291   | 212,707   | 266,520   | 279,742   |
| - R&D Expenses                   | 28,493    | 37,740  | 37,776  | 46,760   | 39,373  | 39,187  | 47,266    | 113,088   | 130,836   | 150,769   |
| Operating Profit                 | 185,523   | 162,954 | 264,169 | 25,843   | 28,785  | 313,057 | 461,652   | 717,163   | 618,891   | 638,489   |
| OP Margin                        | 34.6%     | 38.5%   | 44.0%   | 8.2%     | 4.5%    | 32.2%   | 44.4%     | 44.4%     | 31.9%     | 34.1%     |
| Other Non-operating Profit/Loss* | 22,574    | 7,876   | 10,397  | (13,989) | 12,033  | (4,586) | (26,796)  | (28,756)  | (29,753)  | 26,857    |
| Financial Income/Loss            | 6,366     | 5,318   | 10,264  | (4,822)  | 8,509   | (2,317) | (4,072)   | 35,434    | 17,252    | 17,127    |
| Profit before Income Tax         | 214,463   | 176,147 | 284,830 | 7,033    | 49,327  | 306,154 | 430,784   | 723,840   | 606,390   | 682,473   |
| Net Profit                       | 171,893   | 139,897 | 222,866 | 28,611   | 60,933  | 244,615 | 320,716   | 575,983   | 511,383   | 563,268   |
| NP Margin                        | 32.1%     | 33.1%   | 37.1%   | 9.1%     | 9.5%    | 25.1%   | 30.8%     | 35.6%     | 26.4%     | 30.1%     |

\* Other non-operation profit/loss includes the net gain/loss on equity method valuation



# Quarterly Sales Mix

[Unit: KRW billion]

|               |                   | Adjusted* |      |      |      | Publicly Disclosed |      |      |      |      |      |      |
|---------------|-------------------|-----------|------|------|------|--------------------|------|------|------|------|------|------|
|               |                   | 1Q23      | 2Q23 | 3Q23 | 4Q23 | 1Q23               | 2Q23 | 3Q23 | 4Q23 | 1Q24 | 2Q24 | 3Q24 |
| Sales Revenue |                   | 635       | 620  | 833  | 585  | 598                | 524  | 672  | 383  | 737  | 875  | 882  |
| Biologics     |                   | 450       | 497  | 623  | 400  | 413                | 380  | 462  | 198  | 651  | 774  | 810  |
| Core Products |                   | 359       | 366  | 462  | 269  | 246                | 200  | 206  | 146  | 437  | 541  | 468  |
|               | Remsima IV        | 239       | 239  | 295  | 220  | 114                | 90   | 171  | 145  | 299  | 363  | 317  |
|               | Truxima           | 74        | 82   | 108  | 5    | 113                | 64   | 16   | 0    | 101  | 115  | 102  |
|               | Herzuma           | 46        | 45   | 59   | 44   | 19                 | 46   | 20   | 1    | 37   | 62   | 49   |
|               |                   |           |      |      |      |                    |      |      |      |      |      |      |
| New Products  |                   | 91        | 131  | 161  | 132  | 167                | 180  | 256  | 52   | 214  | 233  | 342  |
|               | Remsima SC        | 66        | 81   | 101  | 74   | 165                | 30   | 86   | 9    | 112  | 111  | 171  |
|               | Yuflyma           | 21        | 32   | 47   | 42   | 2                  | -    | 129  | 4    | 67   | 80   | 94   |
|               | Vegzelma          | 4         | 18   | 13   | 15   | -                  | -    | 41   | 40   | 35   | 40   | 69   |
|               | Zymfentra         | -         | -    | -    | -    | -                  | -    | -    | -    | -    | 2    | 6    |
|               | Others            | -         | -    | -    | -    | -                  | 150  | -    | -    | -    | -    | 2    |
|               |                   |           |      |      |      |                    |      |      |      |      |      |      |
| Non-Biologics |                   | 185       | 123  | 210  | 185  | 185                | 144  | 210  | 185  | 86   | 101  | 72   |
|               | CT Pharm/Chemical | 96        | 95   | 93   | 88   | 96                 | 116  | 93   | 88   | 81   | 95   | 65   |
|               | CMO               | -         | -    | 60   | 45   | -                  | -    | 60   | 45   | -    | -    | -    |
|               | Others            | 89        | 28   | 57   | 52   | 89                 | 28   | 57   | 52   | 5    | 6    | 7    |
|               |                   |           |      |      |      |                    |      |      |      |      |      |      |

\* For comparability, 2023 Biopharmaceutical sales are the pre-merger Celltrion Healthcare's sales, while non-biopharmaceutical sales are Celltrion's sales

# Shareholder Return Policy



\* Target cash dividend set based on (EBITDA – CAPEX) given large R&D and CAPEX needs of the business

Advanced Therapeutics within Everyone's Reach

---

# Thank you

